<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02509234</url>
  </required_header>
  <id_info>
    <org_study_id>TrI.PReSarc V150429</org_study_id>
    <nct_id>NCT02509234</nct_id>
  </id_info>
  <brief_title>Trabectedin and Irinotecan for Refractory Pediatric Sarcomas</brief_title>
  <acronym>TrIPReSarc</acronym>
  <official_title>Trabectedin and Irinotecan in Pediatric Refractory Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate patients with refractory childhood sarcomas, who have
      been treated with a combination therapy of trabectedin and irinotecan (within compassionate
      use), to determine, if this is a promising treatment option with acceptable toxicity and if
      the results warrant a prospective study.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity during therapy</measure>
    <time_frame>As long as patient is undergoing therapy/ 6 months</time_frame>
    <description>WHO toxicity grading</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Assessment of quality of life at the day before starting the next cycle and at months 3, 6, 9 and 12 after start of treatment, using adapted Karnofsky Score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of therapeutic effect</measure>
    <time_frame>12 months</time_frame>
    <description>Read out after every two cycles (functional imaging, PET-MRT/PET-CT), evaluation according to RECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of time to treatment failure</measure>
    <time_frame>12 months</time_frame>
    <description>Read out after every two cycles (functional imaging, PET-MRT/PET-CT), evaluation according to RECIST.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survival in comparison to matched controls.</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of overall survival in a matched pair analysis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Differences in response rate comparing response rate in Ewing Sarcoma to response rate in Soft Tissue Sarcoma</measure>
    <time_frame>12 months</time_frame>
    <description>Statistical comparison of response rate according to RECIST in Ewing Sarcoma vs. Soft Tissue Sarcoma</description>
  </other_outcome>
  <other_outcome>
    <measure>Event free survival in comparison to matched controls.</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of event free survival in a matched pair analysis.</description>
  </other_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Recurrent Childhood Soft Tissue Sarcoma</condition>
  <condition>Recurrent Ewing Sarcoma</condition>
  <condition>Recurrent Rhabdomyosarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined chemotherapy with trabectedin followed by irinotecan</intervention_name>
    <description>Day 1:
Trabectedin 1,1 - 1,5 mg/m²/day i.v.
Day 3-5 and 10-12:
Irinotecan 30- 90 mg/m²/day p.o. or i.v.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adolescents and young adults (age10 - 40 yoa) with refractory sarcoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adolescents and young adults (age10 - 40 yoa) with refractory sarcoma, for which there
             are presently no further treatment options in EURO-Ewing/ EURAMOS/CWS (i.e. ≥ second
             relapse in ES, resistance to surgery in osteosarcoma, relapsed rhabdomyosarcoma) and
             have been treated with a combined chemotherapy of trabectedin and irinotecan
             (described in intervention)

          -  existing matched control in existing study databases

          -  have started of treatment within three months of last progress

        Key Exclusion Criteria:

          -  Patients newly diagnosed or in first relapse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Burdach, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Kinderklinik München Schwabing - Klinik und Poliklinik für Kinder- und Jugendmedizin, Klinikum Schwabing, Städtisches Klinikum München GmbH und Klinikum Rechts der Isar (AöR) der Technischen Universität München</affiliation>
  </overall_official>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2015</study_first_submitted>
  <study_first_submitted_qc>July 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2015</study_first_posted>
  <last_update_submitted>July 24, 2015</last_update_submitted>
  <last_update_submitted_qc>July 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric sarcomas</keyword>
  <keyword>Ewing sarcoma</keyword>
  <keyword>rhabdomyosarcoma</keyword>
  <keyword>soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

